XBiotech Inc. (NASDAQ:XBIT - Get Free Report) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 800,100 shares, a decline of 23.1% from the February 28th total of 1,040,000 shares. Based on an average daily volume of 63,700 shares, the short-interest ratio is presently 12.6 days. Currently, 4.1% of the company's shares are short sold.
Hedge Funds Weigh In On XBiotech
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of XBiotech by 68.2% in the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock valued at $58,000 after purchasing an additional 5,930 shares in the last quarter. Virtu Financial LLC acquired a new position in XBiotech during the fourth quarter valued at $58,000. Bank of America Corp DE lifted its stake in XBiotech by 42.0% in the 4th quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock worth $79,000 after acquiring an additional 5,887 shares in the last quarter. Jane Street Group LLC acquired a new stake in XBiotech during the 3rd quarter worth about $86,000. Finally, MetLife Investment Management LLC purchased a new position in XBiotech during the 3rd quarter valued at about $94,000. Institutional investors and hedge funds own 55.70% of the company's stock.
XBiotech Stock Performance
Shares of NASDAQ:XBIT traded down $0.19 during midday trading on Thursday, reaching $2.95. The company had a trading volume of 53,546 shares, compared to its average volume of 78,246. The company has a fifty day simple moving average of $3.27 and a two-hundred day simple moving average of $5.26. The firm has a market cap of $89.94 million, a price-to-earnings ratio of -2.73 and a beta of 1.28. XBiotech has a 1-year low of $2.92 and a 1-year high of $9.96.
XBiotech (NASDAQ:XBIT - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.34) EPS for the quarter.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Featured Articles
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
